BACKGROUND: The most frequent second malignant neoplasm after retinoblastoma is osteosarcoma, which may be associated with radiation therapy or arise de novo in patients with bilateral retinoblastoma. METHODS: Clinical, pathologic, and diagnostic imaging findings in two patients with Ewing sarcoma (ES) and one with peripheral neuroepithelioma (PN) are presented. RESULTS: Second malignant neoplasms located in the extremities or pelvis were seen 12-18 years after initial diagnosis of unilateral (two patients) or bilateral (one patient) retinoblastoma. The patients with unilateral retinoblastoma were treated by enucleation only; the other received ocular radiation therapy and chemotherapy. To the knowledge of the authors, this is the first documentation of round blue cell tumor after unilateral retinoblastoma. CONCLUSIONS: ES and PN should be included in the differential diagnosis of malignant neoplasms occurring after treatment of unilateral or bilateral retinoblastoma.
BACKGROUND: The most frequent second malignant neoplasm after retinoblastoma is osteosarcoma, which may be associated with radiation therapy or arise de novo in patients with bilateral retinoblastoma. METHODS: Clinical, pathologic, and diagnostic imaging findings in two patients with Ewing sarcoma (ES) and one with peripheral neuroepithelioma (PN) are presented. RESULTS: Second malignant neoplasms located in the extremities or pelvis were seen 12-18 years after initial diagnosis of unilateral (two patients) or bilateral (one patient) retinoblastoma. The patients with unilateral retinoblastoma were treated by enucleation only; the other received ocular radiation therapy and chemotherapy. To the knowledge of the authors, this is the first documentation of round blue cell tumor after unilateral retinoblastoma. CONCLUSIONS: ES and PN should be included in the differential diagnosis of malignant neoplasms occurring after treatment of unilateral or bilateral retinoblastoma.
Authors: Kevin B Jones; Joshua D Schiffman; Wendy Kohlmann; R Lor Randall; Stephen L Lessnick; Lisa A Cannon-Albright Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-17 Impact factor: 4.254
Authors: R L Randall; S L Lessnick; K B Jones; L G Gouw; J E Cummings; L Cannon-Albright; J D Schiffman Journal: J Oncol Date: 2010-03-15 Impact factor: 4.375
Authors: Fabian Wolpert; Michael A Grotzer; Felix Niggli; Dieter Zimmermann; Elisabeth Rushing; Beata Bode-Lesniewska Journal: Sarcoma Date: 2016-07-25